Daiichi Sankyo and AstraZeneca's Datopotamab Deruxtecan Falls Short on Survival in Breast Cancer Trial
Portfolio Pulse from Benzinga Newsdesk
Daiichi Sankyo and AstraZeneca's drug, datopotamab deruxtecan, did not achieve statistical significance in overall survival in a breast cancer trial, despite previous success in progression-free survival. The drug is being developed as a potential treatment option for metastatic breast cancer.
September 23, 2024 | 6:42 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AstraZeneca's datopotamab deruxtecan did not achieve statistical significance in overall survival in a breast cancer trial, impacting its potential as a treatment option. However, it previously showed success in progression-free survival.
The failure to achieve statistical significance in overall survival could negatively impact AstraZeneca's stock in the short term, as it affects the drug's potential marketability. However, the previous success in progression-free survival and ongoing regulatory discussions may mitigate some negative impacts.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80